Physician profile
Deepesh S Patel
NPI 1720022486
$4,429.92
in general payments reported to CMS, 2019-2025
24 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,880 · 2020: $968 · 2021: $322 · 2022: $183 · 2023: $325 · 2024: $210 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.82 |
| Education | $119.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $980.72 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $693.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $648.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.90 | 2020-2025 | Ofev |
| Neurocrine Biosciences, INC. | $277.72 | 2022-2024 | Ingrezza |
| Lilly USA, LLC | $249.82 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $183.48 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $152.93 | 2019-2025 | Airsupra |
| Avanir Pharmaceuticals, INC. | $146.74 | 2019 | |
| Mylan Specialty L.P. | $141.28 | 2020-2024 | Yupelri |
| Abbvie INC. | $119.68 | 2023-2024 | |
| Amgen INC. | $105.98 | 2022-2025 | Otezla |
| Scilex Pharmaceuticals INC. | $83.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.79 | 2019-2020 | |
| Novo Nordisk INC | $52.98 | 2019-2025 | Ozempic, Rybelsus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $32.61 | 2019 | |
| Janssen Biotech, INC. | $30.89 | 2019 | |
| Insulet Corporation | $26.00 | 2025 | Omnipod |
| Allergan, INC. | $17.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.46 | 2020 | |
| Boston Scientific Corporation | $15.09 | 2020 | |
| Celgene Corporation | $14.71 | 2019 | |
| Acadia Pharmaceuticals INC | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.